Sharon Mates, Chairman and CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 191,610 shares at $74.59 ($14.1M) on 2024-08-26, disclosed to the SEC on 2024-08-28.
Scheduled sale ($14.1M) by Chairman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.59 | 22,713 | $1.7M | 12.0% |
| 2 | $74.59 | 22,713 | $1.7M | 12.0% |
| 3 | $73.33 | 23,657 | $1.7M | 12.3% |
| 4 | $73.33 | 23,657 | $1.7M | 12.3% |
| 5 | $73.93 | 16,856 | $1.2M | 8.8% |
| 6 | $73.93 | 16,856 |
| $1.2M |
| 8.8% |
| 7 | $72.74 | 32,459 | $2.4M | 16.8% |
| 8 | $72.74 | 32,459 | $2.4M | 16.8% |
| 9 | $73.70 | 240 | $18K | 0.1% |
| Total | $73.53 avg | 191,610 | $14.1M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |
| ITCI | SELL | 2024-02-27 | $3.1M | — | Filing → |